Abstract
Deep brain stimulation (DBS) is a viable treatment for a variety of neurological conditions, however, the mechanisms through which DBS modulates large-scale brain networks are unresolved. Clinical effects of DBS are observed over multiple timescales. In some conditions, such as Parkinson’s disease and essential tremor, clinical improvement is observed within seconds. In many other conditions, such as epilepsy, central pain, dystonia, neuropsychiatric conditions or Tourette syndrome, the DBS related effects are believed to require neuroplasticity or reorganization and often take hours to months to observe. To optimize DBS parameters, it is therefore essential to develop electrophysiological biomarkers that characterize whether DBS settings are successfully engaging and modulating the network involved in the disease of interest. In this study, 10 individuals with drug resistant epilepsy undergoing intracranial stereotactic EEG including a thalamus electrode underwent a trial of repetitive thalamic stimulation. We evaluated thalamocortical effective connectivity using single pulse electrical stimulation, both at baseline and following a 145 Hz stimulation treatment trial. We found that when high frequency stimulation was delivered for >1.5 hours, the evoked potentials measured from remote regions were significantly reduced in amplitude and the degree of modulation was proportional to the strength of baseline connectivity. When stimulation was delivered for shorter time periods, results were more variable. These findings suggest that changes in effective connectivity in the network targeted with DBS accumulate over hours of DBS. Stimulation evoked potentials provide an electrophysiological biomarker that allows for efficient data-driven characterization of neuromodulation effects, which could enable new objective approaches for individualized DBS optimization.
Competing Interest Statement
N.M.G. is an industry consultant (NeuroOne, funds to Mayo Clinic). G.A.W. declares intellectual property has been licensed to Cadence Neuroscience and NeuroOne. G.A.W serves on scientific advisory board for NeuroOne Inc., UNEEG Inc., LivaNova Inc., and NeuroPace Inc. B.N.L. declares intellectual property licensed to Cadence Neuroscience (contractual rights waived) and Seer Medical (contractual rights waived); and has been a site investigator (Medtronic EPAS, NeuroPace RESPONSE, Neuroelectrics tDCS for Epilepsy) and industry consultant (Epiminder, Medtronic, Neuropace, Philips Neuro; funds to Mayo Clinic). J.J.V.G. was named inventor for intellectual property licensed to Cadence Neuroscience Inc, which is co-owned by Mayo Clinic, and has been an investigator for the Medtronic EPAS trial, the SLATE trial, and Mayo Clinic Medtronic NIH Public Private Partnership (UH3-NS95495); has owned stock in and has had a consulting contract with Neuro-One; and has been site Primary Investigator in the Polyganics ENCASE II trial, site Primary Investigator in the NXDC Gleolan Men301 trial, and site Primary Investigator in the Insightec MRgUS EP001 trial. Remaining authors declare no competing financial interests.
Funding Statement
National Institute of Mental Health Award R01MH122258. The content is solely the responsibility of the authors and does not represent the official views of the NIH.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Mayo Clinic gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
This work was supported by National Institute of Mental Health Award R01MH122258. The content is solely the responsibility of the authors and does not represent the official views of the NIH.
